Related Experiment Videos
Elevated serum ceruloplasmin levels in subjects with metabolic syndrome: a population-based study
Chul-Hee Kim1, Joong Yeol Park, Jin Yeob Kim
1Department of Internal Medicine, College of Medicine, University of Ulsan, Seoul, Korea.
Insights
Elevated serum ceruloplasmin levels are linked to metabolic syndrome (MS) and impaired glucose regulation. Higher ceruloplasmin indicates increased cardiovascular risk factors in adults.
Area of Science:
- Biochemistry
- Cardiovascular Medicine
- Endocrinology
Background:
- Serum ceruloplasmin is a known cardiovascular disease risk factor.
- Metabolic syndrome (MS) encompasses insulin resistance and related cardiovascular risks.
Purpose of the Study:
- To investigate if serum ceruloplasmin levels are elevated in individuals with metabolic syndrome.
- To explore the association between serum ceruloplasmin and cardiovascular risk factors in a community-based population.
Main Methods:
- Studied 883 South Korean adults over 40 years old.
- Measured serum ceruloplasmin, performed oral glucose tolerance tests.
- Assessed cardiovascular risk factors: lipids, fasting insulin, urinary albumin excretion rate (UAER).
Main Results:
- Subjects with MS had significantly higher serum ceruloplasmin levels (325 mg/L) compared to those without MS (278 mg/L).
- Ceruloplasmin levels increased with worsening glucose tolerance (normal, impaired, diabetes).
- Serum ceruloplasmin positively correlated with age, glucose, lipids, blood pressure, and UAER; negatively with HDL-cholesterol.
Conclusions:
- Elevated serum ceruloplasmin is associated with metabolic syndrome and impaired glucose regulation.
- Serum ceruloplasmin is independently linked to cardiovascular risk factors like triglycerides, HDL-cholesterol, and UAER.
- Higher serum ceruloplasmin may serve as a marker for metabolic stress in MS.
Abstract:
Serum ceruloplasmin was reported to be an independent risk factor for cardiovascular disease. We investigated whether serum ceruloplasmin level is elevated in subjects with metabolic syndrome (MS, insulin resistance syndrome) in a community-based population. A total 883 subjects over 40 years of age were studied among a population of the Chongup district, a rural area of South Korea. Serum ceruloplasmin levels were measured, and oral glucose tolerance tests were performed. Known cardiovascular risk factors, such as serum lipids, fasting insulin level, and urinary albumin excretion rate (UAER), were also measured. Serum ceruloplasmin levels in the subjects with MS (n = 167, 325 +/- 141 mg/L) were significantly higher than in those without MS (278 +/- 93 mg/L, P <.001). The mean ceruloplasmin level also increased as the glucose tolerance worsened (278 +/- 95 mg/L in normal glucose tolerance [NGT], 303 +/- 108 mg/L in impaired glucose regulation, and 328 +/- 148 mg/L in diabetes; P <.001). Serum ceruloplasmin level was positively correlated with age, fasting glucose, postload 2-hour glucose, total cholesterol, triglyceride, systolic blood pressure, diastolic blood pressure, and UAER and negatively with high-density lipoprotein (HDL)-cholesterol. In multiple regression analysis, serum ceruloplasmin level was independently associated with age, fasting glucose, triglyceride, HDL-cholesterol, and UAER. In conclusion, serum ceruloplasmin level is elevated in the subjects with MS, as well as in subjects with impaired glucose regulation or diabetes mellitus. In addition, serum ceruloplasmin level is associated with various cardiovascular risk factors. These results suggest that elevated serum ceruloplasmin level can be a marker for metabolic stresses associated with MS.